Lis Lobo

I am a Biomedical from the Universidade Federal do Rio Grande do Norte, Brazil (2009) with a master’s in Medical Parasitology by Instituto of Higiene and Medicina Tropical, Universidade Nova de Lisboa (IHMT/ UNL) (2012) and a PhD in Biomedical Sciences – speciality of Cellular and Molecular Biology (2019) from the IHMT/ UNL. My PhD thesis focused on the study of antimalarial activity of new endoperoxides, particularly in the identification of potential parasite targets and possible mechanisms of action. From May 2019 to January 2020 I was involved in the project: A small couple against the big three Two for three -243, funded by Fundação para a Ciência e Tecnologia/ Ministério da Educação e Ciência whose main objective was to evaluate and characterize the antimalarial activity of new synthesized compounds. I have been working as a post-doctoral fellow at IHMT on a project that aimed to evaluate the immunogenicity and prophylactic efficacy of Traspain + CDA in the dog model, in the project entitled CRUZIVAX: Vaccine for prevention and treatment of Trypanosoma cruzi infection, funded by European Union´s Horizon 2020 research and innovation programme. The main objective of CRUZIVAX is to bridge the gap between preclinical and clinical development by performing preclinical and clinical phase 1 studies of a needle-free vaccine against T. cruzi with proven efficacy in preclinical models. In the last years, I published 14 articles in journals, organized 2 events, participated in 12 events, co-supervised 5 MSc dissertations, co-supervised 1 work of course completion of LSc and received 1 award. I have expertise in the areas: Parasitology; Malaria, Cell cultures, Parasite cultures; Plasmodium falciparum; Endoperoxides, In vivo antimalarial activity; Antimalarial drug resistance; Vaccines; Trypanosoma cruzi; Chagas desease; Transmission-Blocking; Plasmodium berghei; Plasmodium chabaudi, Trypanosomatid diseases; Animal health; Immune precision medicine; Dendritic cells; Therapeutic.

1. PeX – EXPL/CVT-CVT/0175/2021 – Enfrentar a cardiomiopatia tripanossómica com microRNAs e modelos celulares tridimensionais (3D) – Grant on going since 2022 / Integration into Research Grant Fellow
2. Immune precision medicine as a new opportunity to control canine trypanosomatid diseases: DogIPM – Grant done from 2021 to 2024 / Integration into Research Grant Fellow
3. Vaccine for prevention and treatment of Trypanosoma cruzi infection –
Contract ongoing since 2019 / Post-doc Fellow

1. Prevalence of pfk13 and pfmdr1 polymorphisms in Bounkiling, Southern Senegal – Journal article published in 2021
2. Half-Sandwich Cyclopentadienylruthenium(II) Complexes: A New Antimalarial Chemotype – Journal article published in 2020
3. Building on Surface-Active Ionic Liquids for the Rescuing of the Antimalarial Drug Chloroquine – Journal article published in 2020
4. New endoperoxides highly active in vivo and in vitro against artemisinin-resistant Plasmodium falciparum – Journal article published in 2018
5. In vitro antiplasmodial activity, pharmacokinetic profiles and interference in isoprenoid pathway of 2-aniline-3-hydroxy-1.4-naphthoquinone derivatives – Journal article published in 2018